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license (http://creativetional ethical and legal challenges where participants have diminished decision-making capacity. We
formed a multi-disciplinary team to develop best practices for consent in data-intensive dementia
research. We recommend that consent processes for research and data sharing support decision-
making by persons with dementia, protect them from exploitation, and promote the common good.
Broad consent designed to endure beyond a loss of capacity and combined with ongoing oversight
can best achieve these goals. Persons with dementia should be supported to make decisions and
enabled to express their will and preferences about participation in advance of a loss of capacity. Reg-
ulatory frameworks should clarify who can act as a representative for research decisions. By promot-
ing harmonization of consent practices across institutions, sectors, and countries, we hope to facilitate
data sharing to accelerate progress in dementia research, care, and prevention.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Progress toward understanding and treating dementia has
been painfully slow. In all biomedical research, advances in
research techniques (e.g., genomic sequencing, brain imag-h.org/ga4ghtoolkit/regulatoryandethics/.
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he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).ing) and information technology have led to a marked trend
for gathering, linking, reusing, and sharing rich health-
related data over long periods. It is now widely recognized
that maximizing the societal benefit of health research
almost always entails the timely release of data to the inter-
national research community. Data sharing honors the con-
tributions of research participants, improves the
transparency of research, and facilitates targeted recruitment
for clinical studies. Increasingly, clinicians and health-care
organizations are also expected to share data withimer’s Association. This is an open access article under the CC BY-NC-ND
Box 1
Literature search strategy and selection criteria
We carried out a scoping review of the literature for our research question: What consent and capacity issues impact de-
mentia research and data sharing? We performed database searches using the terms (Dementia OR Alzheimer) AND
Research AND Consent published since 2007 on Web of Science (filters: Topic), PubMed (filters: MeSH and free text; Ti-
tle/abstract), Google Scholar, and SSRN, until July 21st, 2017. French language searches were carried out on SCOPUS and
Google Scholar for the terms (Alzheimer OR demence) AND recherche AND (consentement OR ethique).We experimented
with numerous spelling variations, synonyms, and additional terms (e.g., capacity, competence, and data sharing), but these
did not produce additional findings. Eight hundred fourteen results were reduced to 585 after removing duplicates. Refer-
ences were excluded when purely scientific articles (166), sources not available in English or French (8), incomplete or inac-
cessible sources (13) as well as literature not addressing or only superficially addressing populations with dementia (95),
health research (166), or consent issues (31). The remaining articles were grouped according to key themes established iter-
atively through article review and consensus deliberation of the larger task team, which included consent, decision-making
authority and support, planning in advance, representation, and capacity assessment. Two researchers (A.T., G.D.) reviewed
the titles and abstracts from all references. Full texts were screened, where application of exclusion criteria or key theme
grouping was unclear. An additional 34 articles addressing the key themes were found in reference lists or contributed by
task team members for a total of 116. The literature included systematic reviews, empirical studies of stakeholder per-
spectives and practices, and regulatory and ethical analyses. A complete reference list can be found in Supplementary
Materials. A limitation is that we did not search for literature about consent and capacity issues concerning other neuro-
degenerative conditions (e.g., stroke) or decision-making contexts (e.g., treatment, organ donation, and assisted dying). Such
literature may provide important indirect insights but was too expansive to include, not to mention that some considerations
are condition specific.
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sharing presents opportunities for the dementia research
community to pool high-quality data sets, attain larger sam-
ple sizes, maximize the value drawn from data already
collected, and reduce wasteful—and sometimes harmful—
duplication and delays in research.
Demonstrating the effectiveness of interventions for de-
mentia requires participation of healthy persons and persons
with dementia in clinical studies and biobanks and sharing of
their genomic and health-related data with many re-
searchers. Where research involves physical, psychological,
or privacy risks, researchers are generally required to seek
consent [2,3]. New data types such as whole genome
sequences present risks of participant re-identification,
disclosure of sensitive information about disease risk or bio-
logical relationships, and misuse (discrimination in the
workplace and insurance, stigmatization) [4]. It is therefore
best practice for researchers to seek consent for sharing rich
individual-level data (or the samples they are derived from)
and also to protect these data using encryption, robust access
control and ethical oversight, and network technologies that
maintain secure, local storage while enabling federated ana-
lyses [5]. In general, data or sample sharing between institu-
tions and across borders over long periods raises important
consent challenges [6]. When is consent required? What
form should consent take? Can adequate privacy protections
be ensured between countries and institutions?
Dementia and other disorders of cognitive impairment
are characterized by a progressive diminishment of cogni-tive skills (e.g., memory, reasoning, and language) that
can impact on decision-making capacity. Researchers
seeking consent from persons with dementia confront
ethical and legal uncertainty, such as when and how to
assess capacity to consent [7]. Regulatory frameworks gov-
erning decision-making involving persons with dementia
are relatively clear for treatment, but not for research.
Where rules are supplied for research, they often fail to
accommodate the data sharing practices and digital inter-
connectivity of modern research. Guidance developed for
invasive clinical studies tends to be disproportionately
restrictive when applied to observational research or data
sharing. Most international or national research guidelines
rarely delve into the consent issues for adults with dimin-
ished capacity, deferring instead to unclear or restrictive
local laws. Other laws and ethical guidelines tend to lump
persons with dementia together with other vulnerable pop-
ulations, overlooking ethical concerns specific to adults
with diminishing capacity [8].
Well-meaning safeguards to protect persons with limited
capacity from abuse and exploitation, such as the require-
ment that researchers seek consent from a legally autho-
rized representative (LAR), can function to exclude
persons with dementia from research and data sharing ac-
tivities [2,3]. Disproportionate safeguards hinder
improvements in dementia research, care, and prevention
and undermine the right of persons with dementia to full
and effective participation and inclusion in society [9].
Legal variation across jurisdictions or sectors can
Box 2
International comparative regulatory analysis
We carried out a comparative analysis of international, regional and national legislative, and policy frameworks from eight
countries (Australia, Canada, Finland, France, Japan, Singapore, the United Kingdom, and the United States) that govern
informed consent, substitute decision-making, participation in research, and the processing of personal data. The analysis
comprised both legally binding instruments and nonbinding “soft law” instruments such as declarations and policies. The
jurisdictions were selected to reflect geographic diversity and legal systems diversity, with a focus on countries active in the
domain of data-intensive health research. The detailed methodology of this review is available in a previous publication [17].
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sharing across borders. Such restrictive regulations contra-
dict the views of persons with dementia and their families,
many of whom have positive attitudes toward research
participation [10].
This article identifies legal and ethical uncertainties, re-
strictions, and jurisdictional discrepancies at the intersection
of consent, data sharing, and diminished capacity. The
following six key themes are explored: consent standards,
identifying who has authority to consent, decision-making
support, planning in advance, representation, and capacity
assessment. We concludewith recommendations for consent
to research and data sharing involving persons with demen-
tia, with a view to clarifying fundamental regulatory princi-
ples, and harmonizing consent processes across countries,
institutions, and sectors (clinical, research, and biobanking).
These recommendations are limited to consent and capacity
issues, as other generic challenges for research and data
sharing governance are being addressed elsewhere (e.g.,
anonymization, security safeguards, access processes, over-
sight, return of results, ethics review equivalency across sites
and jurisdictions, and risk-benefit criteria for research with
vulnerable persons) [11,12]. These recommendations are
also founded on empirical evidence of the attitudes of
persons with dementia and their families. Patient
engagement is increasingly recognized as integral to
effective dementia research and ethical research oversight
[13]. We also sought input on the recommendations from
representatives of persons with dementia and researchers.2. Methodology
These recommendations were developed by the Ageing
and Dementia Task Team, established by the Regulatory
and Ethics Work Stream of the Global Alliance for Geno-
mics and Health (GA4GH). The GA4GH is a consortium
of over 500 research institutions, health centers, life science
and IT companies, and patient advocacy groups with a
mission to promote international data sharing to improve hu-
man health. Ten experts were invited to contribute to this
policy, to ensure diverse expertise and geographical repre-
sentation. They included clinician-researchers (M.B., H.B.,
S.G., M.R.), jurists (A.T., A.M., R.H., B.M.K.), ethicists(C.G.), and patient advocates (D.G.) from across Europe,
Australia, and Canada. Experts worked to achieve consensus
on consent issues via teleconferences and exchange of back-
ground literature. They were asked to build on the GA4GH
Framework for Responsible Sharing of Genomic and Health
Related Data (2014) [14], which aims to activate the human
right of everyone to benefit from the progress of science [15]
and GA4GH Consent Policy (2015) [16]. Steps included are
as follows: (1) preliminary policy review and teleconference
to establish the mandate; (2) scoping review of the literature
(Box 1) and international comparative regulatory analysis
(Box 2); and (3) four drafts and rounds of comments by tele-
conference and email. A representative from the European
Working Group of People with Dementia, patient advocates
from Alzheimer Europe, and end users from the researcher-
clinician network INTERDEM all provided valuable com-
ments on drafts of these recommendations (see Acknowl-
edgments).
Our discussion is organized according to six key themes.
Each section reviews important regulatory provisions, issues
raised in the literature, gaps where future work is needed,
and concludes with recommendations.3. Discussion
3.1. Consent
Excluding persons with dementia from full participation
in society, including research, on the basis of age or
disability is discriminatory as per the United Nations
Convention on the Rights of Persons with Disabilities
(CRPDs) and Principles for Older Persons [9,18].
Moreover, including this population in pertinent research
is essential to ensure future patients benefit from
improvements in prevention and care [2,19–22]. Special
attention must be paid to the vulnerabilities of persons
with dementia in research [2,3,23–25]. They require
specific safeguards, distinct from those in place for other
vulnerable populations, to not only protect them from
harm but also to respect their agency [8,26]. For the
collection, linkage, reuse, and sharing of rich individual-
level data, broad consent is emerging as a general best prac-
tice [2,6,16,25,27]. Broad consent as defined by
Box 3
Summary panel of recommendations
Consent
 Consent processes should strike a more explicit balance between supporting decision-making by persons with de-
mentia, protecting them from exploitation, and promoting the common good. Broad consent combined with ongoing
oversight can achieve this balance for the sharing of rich individual-level data.
 Persons with dementia should be presumed to have the capacity to consent unless established otherwise.
Decision-making authority
 Regulatory frameworks should provide clarity about who can act as an LAR for research for persons who lack capacity
to consent.
Support for decision-making
 Persons with dementia should be supported to make their own decisions relating to research and data sharing. Even
where decisions are made by an LAR, they should be included in decision-making in a manner appropriate to their
level of capacity.
Planning in advance
 In advance of a loss of capacity, healthy persons and those with dementia should be supported to express their pref-
erences about future participation in research and data sharing.
 Early communication should be encouraged between persons with dementia, family members, and carers about pref-
erences relating to research and data sharing, while striving not to provoke anxiety about worsening symptoms.
 Consent forms should specify that consent to research or data sharing so provided will be respected after a loss of ca-
pacity.
Representation
 Researchers and LARs should respect the will and preferences of persons with dementia relating to research and data
sharing, including those expressed in advance of a loss of capacity (e.g., through a broad consent), about participation,
receiving results, and representation. Where preferences are unknown, the legally authorized representative should
consider the person’s beliefs, values, and welfare.
Capacity assessment
 Capacity assessment tools need to be developed and validated for persons with dementia participating in genomic
research, biobanking, and data sharing. Research protocols should specify when and how capacity will be (re)assessed.
 Capacity assessment tools should be tailored to a specific decision-making context and should adduce sufficient ev-
idence the person lacks capacity.
 The rigor and regularity of capacity assessment should be proportionate to the risks posed to person’s rights and in-
terests.
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permission to use samples and associated data for a range of
research studies, not specified in detail at the time of
recruitment, subject to ongoing transparency and ethics
oversight (Council for International Organizations of
Medical Sciences/WHO Guidelines, US Common Rule)
[2,27]. Broad consent does raise concerns about privacy
and informational autonomy and tensions with data
protection requirements in some jurisdictions [28,29].
Combining broad consent with ongoing oversight can help
to ensure that privacy is protected, and uses are consistent
with participant expectations. General challenges of
harmonizing and implementing broad consent processes
and ongoing oversight are addressed elsewhere [16]. Broad
consent processes are particularly well suited for data
sharing involving persons with dementia who may not be
able to provide specific consent later on. Indeed, an impor-
tant means of supporting decision-making is enabling per-sons with dementia to express their will and preferences
in advance (see below Section 3.2). They strike a more
explicit balance between supporting decision-making by
persons with dementia, protecting them from exploitation,
and promoting the common good. Where possible, we
recommend seeking recruitment and consent of individuals
into longitudinal studies or registries before symptoms
worsen, which can mitigate later challenges of capacity.
Broad consents should clarify where data will continue to
be used after a loss of capacity. As an additional safeguard,
patient representatives can act as advisers to or be members
of data access committees. Data sharing consent require-
ments, guidelines, language, and interpretation should
also be harmonized across countries and institutions, as
well as across sectors (clinical, research, and biobanking)
to improve certainty about the scope of sharing, facilitate
pooling and linkage, and promote the reuse of data
[14,25,30].
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To respect the dignity and autonomy of participants, re-
searchers should first try to seek consent from the person
with dementia. The influential United Nations CRPD is crit-
ical of proxy consent processes and instead emphasizes
limiting intrusion on legal capacity by supporting
decision-making by persons with mental disability [31,32].
In research contexts, consent processes should ensure that
researchers, family members, and carers all provide
support to persons with dementia to assist participation in
decision-making [9,22,31,33]. There will still be situations
where despite decision-making support, a person with de-
mentia is ultimately found to lack the capacity to consent
to research or data sharing after a formal capacity assess-
ment. In such situations, researchers are generally required
to seek consent from an LAR. In many countries, however,
researchers face difficulties identifying the LAR for research
[10,34–38]. Different categories of LARs apply in different
circumstances, including court-appointed guardians, agents
designated by an advance directive, or one-time surrogate
decision makers designated by statute (e.g., family mem-
bers, carers, or other concerned persons) [17,20,21,39,40].
Research norms do not typically specify who may consent,
but instead defer to local consent and capacity laws.
Unfortunately, local laws may limit or restrict LAR
authority to consent to research participation or impose
prohibitive requirements such as court approval [21,41].
Acceptable risk/benefit thresholds determining when an
LAR can consent to research vary confusingly across
jurisdictions and research sectors. Traditional requirements
are that research directly benefits the individual or be
limited to minimal risk research that benefits individuals
of the same age or disease group [3,42]. But, risk
thresholds are not coordinated across regulatory
frameworks, making it unclear who can act as LAR to
research participation. In addition, researchers and family
members may have false assumptions about regulatory
requirements [43]. In any case, persons without supportive
family or carers may be excluded from research (and its ben-
efits) because they lack representation [44]. Regulatory
divergence between countries adopting or not adopting the
CRPDmay threaten international collaboration. Researchers
from CRPD countries may not be allowed to use data
collected under LAR consent in noncompliant ones.
Following the lead of the Council for International Organi-
zations of Medical Sciences/WHO Guidelines and US Com-
mon Rule revisions, regulatory frameworks should provide
more clarity about who can act as LAR for research
[2,27]. Recognizing the importance of including
vulnerable populations in research, a proportionate
approach to risk-benefit is increasingly adopted, especially
for data sharing [2,14]. We recommend that persons with
dementia be supported to make their own decisions about
research participation and data sharing (see Section 3.3).
They should be presumed to have the capacity to do so, un-less established otherwise (see Section 3.6). In advance of a
loss of capacity, both healthy persons and those with demen-
tia should be supported to designate representatives and to
express their preferences about participation in research
and data sharing (see Section 3.4).3.3. Support for decision-making
Given the nature and complexity of research, and the
related risks and benefits, it may be difficult for persons
with diminished capacity to satisfy high informed consent
standards. Decision-making can be supported by simplifying
consent forms, providing visual or memory aids, taking
interactive or educational approaches (where persons with
dementia are asked to explain their understanding of consent
elements), re-explaining misunderstood information, or
involving familiar carers to facilitate explanation and
communication of a decision [45–49]. In a process consent
approach, researchers come to know the participant and to
tailor consents to his or her preferred means of
communication [50]. More work is needed to determine
how consent supports can be effectively adapted for persons
with dementia. In practice, decision-making with persons
with dementia is often a collaborative process [51]. Research
ethics guidelines generally promote supported or shared
decision-making and may require researchers to seek an
affirmation from persons with dementia of their willingness
to participate (assent) and to respect objections to continued
participation (dissent) [2,3,48,51]. A remaining controversy
is whether researchers or LARs should be obliged to respect
an “uninformed” objection to participate by a person or
simply take it into account [20]. To safeguard respect for hu-
man dignity, we recommend that researchers, family mem-
bers, carers, and LARs take all reasonable efforts to
support persons with dementia to make their own decisions,
relating to research and data sharing. Even where decisions
are made by an LAR, efforts should be made to include per-
sons with dementia in decision-making in a manner appro-
priate to their level of capacity. Consent processes
involving persons with dementia may therefore require addi-
tional steps, expertise, and resources. Policy makers, fun-
ders, and researchers should be sensitive to the social and
psychological pressures facing persons with dementia, fam-
ily members, and carers and the environments from which
persons with dementia are recruited [52].3.4. Planning in advance
Onemeans of supporting decision-making is to allow per-
sons to appoint a representative and/or to specify their will
and preferences in advance [9,38,53]. Empirical studies
show that most older adults with dementia are willing to
provide consent to some forms of research in advance or
to allow a representative to do so [10,54]. Some guidelines
highlight the importance of respecting or taking into
account expressed wishes [23]. A few recognize the
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frameworks do not, however, consistently authorize
individuals to provide binding instructions in advance or to
designate an agent in advance to make decisions relating
to research or data sharing [17,21,55,56]. There is also
significant regulatory variation over the formalities of
advance directives and the extent to which they may be
overridden by a health professional or family member. The
effectiveness of advance directives for research, especially
“positive” ones (“I wish to be included”), is limited by the
high standard of informed consent in research; the
unknown, complex nature of future research; a lack of
awareness and uptake by the public; and difficulties
persons with dementia face participating in research
without the practical support of family and carers [57]. Phi-
losophers debate whether advance directives remain legiti-
mate if preferences, and even identity, fundamentally
change over time or as symptoms evolve [57,58].
Especially in longitudinal research, the question arises
whether consent can be presumed to “endure” after a loss
of capacity [59]. This issue will remain controversial for
experimental research, where clear protocols are needed to
determine when capacity will be reassessed. For sample
and data sharing, however, broad consent processes already
explicitly encode “precedent autonomy”. They can be de-
signed to capture thewill and preferences of persons with de-
mentia expressed in advance of a loss of capacity (e.g.,
through a broad consent), such as preferences about partici-
pation, receiving results, or who represents them. To alle-
viate uncertainty, we recommend that consent forms
should specify that consent to research or data sharing so
provided will be respected after a loss of capacity, unless
the person dissents or the LAR withdraws (following the
appropriate decision-making standard) [21]. Jurisdictions
recognizing advance directives may be more accepting of
durable broad consent. More generally, policy makers and
researchers should encourage early communication between
persons with dementia, family members, and carers about
preferences relating to research and data sharing, while striv-
ing not to provoke anxiety about worsening of symptoms
[41]. Current societal efforts to encourage individuals to ex-
press instructions or wishes about personal care—in living
wills, health records, or even government registries—could
be expanded to address research and data sharing. This
would reduce the need for repeated advance planning discus-
sions. The uptake, effectiveness, and empathy of advance
planning can also be improved by structured, educational
discussions held over time that include trained facilitators
and representatives [60].3.5. Representation
The public and persons with dementia support LAR
consent to research, particularly for low-risk research
[10,34–38]. But, what decision-making standard should an
LAR follow? Standards vary across countries and researchsectors, and research ethics committees may interpret these
standards differently [17,20,21,61]. Traditional guardianship
approaches emphasize that LARs should focus on the
person’s “best interests” or welfare [33]. Substituted judg-
ment standards focus more on the person’s expressed
wishes, values, and beliefs and ask the LAR to substitute
the judgment of the person with dementia for their own
[62]. Emerging agency models emphasize respect for the
“will and preferences” of the person [31,63]. In the
research context, best interests approaches protect against
exploitation, but they can be exclusionary, especially for
nontherapeutic research [62,64]. For research and data
sharing decisions, the will and preferences of persons with
dementia are often unknown, and it may be difficult to
render substitute judgments based on vague values and
beliefs [17,61,65]. There are also concerns about the
accuracy of decisions by LARs because of the potential
for therapeutic misconception and conflicts of interest
[66,67]. Future work is needed on how best to hear the
preferences of people with more complex support needs
and how to establish oversight of LARs proportionate to
the risks posed to the person’s rights and interests [68].
We recommend that LARs involved in decision-making
relating to research or data sharing should respect the known
will and preferences of the person with dementia. Ascertain-
ing the will and preferences may require the LAR to consult
persons with dementia, advance planning documents, as
well as family members and carers. Researchers should
inform LARs exercising rights on behalf of persons with de-
mentia (e.g., to withdraw consent) of known wishes ex-
pressed by the persons with dementia (e.g., a broad
consent) and should encourage LARs to respect such
wishes. Where the will and preferences of persons with de-
mentia cannot be ascertained, LARs should make decisions
on behalf of persons with dementia that take into account
the person’s beliefs, values, and welfare. Transparent pro-
cesses should be in place for reporting failures of re-
searchers or LARs to respect proxy decision-making
standards, and for adjudicating disputes. For minimal risk
research and data sharing, it may be practical to extend
more deference to LARs. Readers should respect locally
applicable standards that differ from these recommenda-
tions.3.6. Capacity assessment
Researchers have an ethical and legal obligation to ensure
that persons with dementia have the capacity to consent or
refuse to participate in research or data sharing. Simply
assuming lack of appropriate capacity because of a diagnosis
of dementia, or because a person makes a decision that
seems eccentric or unwise, may be discriminatory [31].
Functional capacity assessments are typically used in a
biomedical context, in which a health-care provider evalu-
ates a person’s ability to understand relevant information,
to appreciate consequences, to reason, and to express a
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appreciation of the purpose, procedures, risks, and benefits
of a specific project or data sharing initiative [69]. Assess-
ment is especially challenging for longitudinal research,
however, because capacity may fluctuate in the short and
long term [22,69–72]. Decision-making may need to be de-
layed to see if capacity returns. Capacity assessment is a
time- and context-specific process. Generic tests and test
thresholds cannot be established. Instead, they should be
proportionate to the risks to the individual’s rights and inter-
ests, to balance risks of exploitation against risks of discrim-
ination. Persons with dementia who lack the capacity to
consent to one type of treatment or research participation
may retain the capacity to consent to less risky or complex
research or to data sharing (if relevant). Those lacking the
capacity to make certain decisions may still have the capac-
ity to appoint an LAR to make decisions on their behalf [73].
A number of assessment tools have been adapted from the
treatment to the research domain [46,74–76]. There
remains no gold standard, and most tools rely on the
professional (and potentially biased) judgment of a
member of the research team [21,77]. Tools still need to
be developed and validated for persons with dementia
participating in genomic research, biobanking, and data
sharing [26]. Notions of capacity likely differ significantly
across cultures, complicating harmonization of regulation
and research data governance. This could result in barriers
to international research collaborations, where relying on
data from other countries might be considered exploitative
(for countries with less rigorous assessment or lower thresh-
olds) or discriminatory (for countries with more rigorous as-
sessments or higher thresholds). Fortunately, more
widespread adoption of supported decision-making and in-
clusion of persons with dementia in decision-making will
diminish the consequences of variation in this area.
We recommend that researchers presume that persons with
dementia have capacity, until demonstrated otherwise. Capac-
ity assessment tools should be tailored to a specific decision-
making context and should adduce sufficient evidence the per-
son lacks capacity (and not vice versa). They should also be
standardized and validated with respect to the research proto-
col and associated risks. Capacity may need to be reassessed
over time, for example, at different research stages or on re-
contact. The research protocol should specify when and how
participants’ capacity will be reassessed. Routine, formal ca-
pacity assessment can be difficult for both persons with de-
mentia and researchers, so the rigor and regularity of
assessment should be proportionate to the risks posed to per-
son’s rights and interests. For minimal risk research or data
sharing, capacity assessment may be integrated with an inter-
active consent process including a questionnaire [78], poten-
tially facilitated by a family member or carer. For riskier
studies, a staged approach is advisable, moving on in cases
of uncertainty from brief screening tools to formal, rigorous
assessments [76]. Similarly, test thresholds should be propor-
tionate to risks, to limit incursion on the individual’s auton-omy. Capacity of persons with dementia to form an advance
directive and capacity of representatives (e.g., ageing care-
givers) should also be considered.4. Conclusion
The last decade has seen a substantial increase in genomic-
and health-related data generated about patients with demen-
tia. The systematic collection, storage, and sharing of large
sets of research data are increasingly central to understanding
aging and dementia. Collaboration between governments, re-
searchers, health-care institutions, and industries is essential
but is hindered by legal uncertainty and restrictiveness, espe-
cially with regards to persons with diminishing capacity to
consent. Researchers still struggle to determine if persons
with dementia can be included in research or if their data
can be shared. They lack tools and know-how for supporting
persons with dementia to make their own decisions or for
determining when they are unable to do so. Regulatory frame-
works remain unclear about who, if anyone, can provide con-
sent on behalf of a person with dementia to research
participation. Moreover, when LARs are asked to provide
consent, they face uncertainty over how to balance previous
instructions and wishes with current wishes and welfare con-
siderations. Divergence in how countries resolve these ques-
tions may come to undermine international collaboration.
Our recommendations aim to facilitate researcher compli-
ance with applicable laws and guidelines and encourage the
harmonization of regulatory frameworks and research gover-
nance. Central recommendations are summarized in Box 3.
Though these recommendations focus on persons with de-
mentia, they may well serve as a model for consent to
research and data sharing involving adults with other condi-
tions affecting decision-making capacity (e.g., stroke and
traumatic brain injury), with appropriate modifications and
patient engagement. Future guidance is needed for related
decision-making contexts, such as when to provide family
members with access to the genomic- and health-related
data of persons with dementia and how to handle the return
of individual results from dementia research.Acknowledgments
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1. Systematic review: This manuscript is based on a
scoping literature review covering previous system-
atic reviews, empirical studies of stakeholder per-
spectives, and regulatory and ethical analyses, as
well as a comparative analysis of international,
regional and national (eight countries) law and policy
frameworks.
2. Interpretation: This manuscript, drawing on human
rights developments, integrates analysis and recom-
mendations across a range of consent issues in de-
mentia research: legal authority, decision-making
support, planning in advance, ethical representation,
and capacity assessment.
3. Future directions: This manuscript identifies areas
for future exploration: (a) clarifying who can act as
the legally authorized representative for research
across jurisdictions; (b) adapting consent supports
for persons with dementia; (c) improving the uptake
and accuracy of advance planning tools; (d) devel-
oping principles for research related decision-mak-
ing by representatives; and (e) developing and
validating capacity assessment tools for persons
with dementia participating in data-intensive health
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